RAPP · XBRL financial data

Rapport Therapeutics financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RAPP's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	—	—	—	0	0	0	—	20,000	0	0
Research and development	15,689	15,543	17,199*	19,572	22,680	22,279	30,258*	32,716	51,414	34,316
Selling, general and administrative	—	—	—	7,536	6,816	7,707	—	11,499	9,392	9,770
General and administrative	5,111	6,097	6,322*	7,536	6,816	7,707	8,251*	—	—	—
Total operating expenses	20,800	21,640	23,521*	27,108	29,496	29,986	38,509*	44,215	60,806	44,086
Operating income (loss)	(20,800)	(21,640)	(23,521)*	(27,108)	(29,496)	(29,986)	(38,509)*	(24,215)	(60,806)	(44,086)
Interest income	2,679	4,103	3,541*	3,045	2,764	3,061	4,746*	4,358	4,191	3,851
Income tax expense (benefit)	—	—	year only	—	—	—	year only	—	—	—
Net income (loss)	(18,121)	(17,537)	(19,980)*	(24,063)	(26,732)	(26,925)	(33,763)*	(19,857)	(56,615)	(40,235)
Earnings per share, basic USD per share	(1.70)	(0.50)	—	(0.68)	(0.75)	(0.71)	(0.72)*	(0.42)	(1.19)	(0.84)
Earnings per share, diluted USD per share	(1.70)	(0.50)	—	(0.68)	(0.75)	(0.71)	(0.72)*	(0.42)	(1.19)	(0.84)
Weighted average shares, basic thousands of shares	10,667	34,856	—	35,267	35,445	37,931	46,978*	47,237	47,473	47,769
Weighted average shares, diluted thousands of shares	10,667	34,856	—	35,267	35,445	37,931	46,978*	47,237	47,473	47,769

Balance sheet

CSV

Fiscal quarters (RAPP's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	110,164	39,314	56,805	57,604	55,067	251,359	52,645	78,056	63,612	74,754
Short-term investments	225,975	281,347	248,475	227,778	205,380	261,667	437,894	398,726	372,465	320,275
Accounts receivable	—	—	—	—	—	—	0	58	293	171
Prepaid and other current assets	4,422	5,173	4,417	5,481	9,690	7,528	7,917	7,750	10,381	12,076
Total current assets	340,666	325,939	309,802	290,968	270,242	520,659	498,561	484,695	446,856	407,381
Property and equipment, net	3,474	3,409	3,529	3,404	3,172	3,116	2,976	2,518	2,337	1,957
Right-of-use asset	1,769	1,607	1,442	7,470	11,047	10,480	9,909	9,327	8,732	8,125
Total assets	346,098	331,144	314,933	302,053	285,495	535,323	512,431	497,597	458,982	418,558
Accounts payable	1,875	1,323	1,954	2,139	3,176	3,235	4,190	6,561	2,796	1,718
Accrued liabilities	5,517	5,056	6,076	6,236	6,944	8,599	12,104	8,721	23,155	16,259
Total current liabilities	8,095	7,099	8,767	9,383	11,879	14,316	19,049	17,897	28,424	20,302
Lease liability, non-current	1,117	931	739	6,834	10,104	9,390	8,729	8,188	7,632	7,066
Total liabilities	9,212	8,030	9,506	16,217	21,983	23,706	27,778	26,085	36,056	27,368
Accumulated deficit	(86,228)	(103,765)	(123,745)	(147,808)	(174,540)	(201,465)	(235,228)	(255,085)	(311,700)	(351,935)
Total stockholders' equity	336,886	323,114	305,427	285,836	263,512	511,617	484,653	471,512	422,926	391,190
Total liabilities and equity	346,098	331,144	314,933	302,053	285,495	535,323	512,431	497,597	458,982	418,558
Common shares outstanding (cover page) thousands of shares	36,576	36,576	36,496	36,498	36,498	47,661	47,793	47,827	47,978	59,280

Cash flows

CSV

Fiscal quarters (RAPP's year ends in late December)

In thousands of dollars	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(18,121)	(17,537)	(19,980)*	(24,063)	(26,732)	(26,925)	(33,763)*	(19,857)	(56,615)	(40,235)
Stock-based compensation	2,354*	3,182*	3,208*	4,040	4,389*	4,735*	5,691*	6,963	7,202*	7,634*
Depreciation and amortization	208*	219*	260*	244	252*	256*	265*	227	212*	198*
Net cash from operating activities	(16,352)*	(16,415)*	(14,446)*	(20,237)	(25,070)*	(17,465)*	(24,701)*	(13,061)	(41,455)*	(41,633)*
Purchases of property and equipment	967*	140*	226*	291	22*	134*	169*	86	78*	0*
Net cash from investing activities	(107,104)*	(53,041)*	31,930*	21,031	22,596*	(56,776)*	(174,324)*	37,941	25,600*	51,064*
Net cash from financing activities	159,353*	(1,394)*	7*	5	(63)*	270,533*	311*	531	1,411*	1,711*
Net change in cash	35,897*	(70,850)*	17,491*	799	(2,537)*	196,292*	(198,714)*	25,411	(14,444)*	11,142*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Rapport Therapeutics	74,754	0	(41,633)*	59.3M	12.3 quarters	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Ocugen	24,632	1,951	(15,739)*	339.3M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.